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ORIGINAL ARTICLE
The degradation of p53 and its major E3 ligase Mdm2 is
differentially dependent on the proteasomal ubiquitin receptor S5a
A Sparks1, S Dayal1, J Das1, P Robertson2, S Menendez3 and MK Saville1
p53 and its major E3 ligase Mdm2 are both ubiquitinated and targeted to the proteasome for degradation. Despite the importance
of this in regulating the p53 pathway, little is known about the mechanisms of proteasomal recognition of ubiquitinated p53 and
Mdm2. In this study, we show that knockdown of the proteasomal ubiquitin receptor S5a/PSMD4/Rpn10 inhibits p53 protein
degradation and results in the accumulation of ubiquitinated p53. Overexpression of a dominant-negative deletion of S5a lacking
its ubiquitin-interacting motifs (UIM)s, but which can be incorporated into the proteasome, also causes the stabilization of p53.
Furthermore, small-interferring RNA (siRNA) rescue experiments confirm that the UIMs of S5a are required for the maintenance of
low p53 levels. These observations indicate that S5a participates in the recognition of ubiquitinated p53 by the proteasome.
In contrast, targeting S5a has no effect on the rate of degradation of Mdm2, indicating that proteasomal recognition of Mdm2 can
be mediated by an S5a-independent pathway. S5a knockdown results in an increase in the transcriptional activity of p53. The
selective stabilization of p53 and not Mdm2 provides a mechanism for p53 activation. Depletion of S5a causes a p53-dependent
decrease in cell proliferation, demonstrating that p53 can have a dominant role in the response to targeting S5a. This study
provides evidence for alternative pathways of proteasomal recognition of p53 and Mdm2. Differences in recognition by the
proteasome could provide a means to modulate the relative stability of p53 and Mdm2 in response to cellular signals. In addition,
they could be exploited for p53-activating therapies. This work shows that the degradation of proteins by the proteasome can be
selectively dependent on S5a in human cells, and that this selectivity can extend to an E3 ubiquitin ligase and its substrate.
Oncogene (2014) 33, 4685–4696; doi:10.1038/onc.2013.413; published online 14 October 2013
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INTRODUCTION
The covalent conjugation of ubiquitin to proteins can target them
for degradation by the 26S proteasome.1 This is composed of two
multi-protein complexes:2–4 the 20S core and the 19S regulatory
particle (RP). Protein degradation takes place in the central cavity
of the 20S core. The 19S RP participates in the recruitment of
ubiquitinated proteins. It also mediates protein deubiquitination,
unfolding and translocation, and opens the gated entrance to the
20S core.
Ubiquitin-dependent recognition of substrates by the protea-
some involves ubiquitin-binding receptors. Studies in lower
organisms show that particular ubiquitin receptors participate in
the recognition of specific subsets of ubiquitinated proteins.5,6
Much remains to be learned regarding the identity and precise
roles of proteasome-targeting ubiquitin receptors in man. The
degree of substrate selectivity of ubiquitin receptors is unclear.
In addition, the therapeutic potential of targeting ubiquitin-
binding proteins has not been adequately explored. Bortezomib,
an inhibitor of the proteolytic activity of the proteasome, is used in
the treatment of some cancers.7,8 Blocking proteasomal
recruitment is an alternative mechanism for interfering with
protein degradation by the proteasome.
There are over 20 families of ubiquitin-binding domains that are
present in more than 200 proteins.9 These proteins are involved in
mediating a number of ubiquitin-dependent processes, and it is
unclear how many of them are involved in proteasomal
recruitment. S5a/PSMD4/Rpn10 and ADRM1/Rpn13 are intrinsic
subunits of the 19S RP that bind ubiquitin and are involved in
substrate recognition.10–13 There is evidence for additional
ubiquitin-binding activity in the 19S RP.14,15 A substantial
proportion of S5a is extraproteasomal.16–19 It remains to be
established whether this participates in bringing ubiquitinated
substrates to the proteasome. There are also other ubiquitin
receptors that associate transiently with the proteasome in
substoichiometric amounts. These receptors are thought to be
involved in the shuttling of ubiquitinated proteins to the
proteasome. A class of adaptor proteins contain a proteasome-
binding ubiquitin-like (UBL) domain and a ubiquitin-binding
ubiquitin-associated (UBA) domain.11–13,20 Human S5a and
ADRM1 interact with UBL domains in UBA/UBL proteins.10,21,22
Recruitment of proteins to the proteasome by S5a and ADRM1
could involve direct interaction with ubiquitinated substrates and/
or indirect interactions bridged by adaptor proteins. Additional
proteasome subunits may also interact with UBL domains,12,23 and
there are ubiquitin-binding proteins that associate with the
proteasome independently of UBL domains.24–26
Mdm2 is a key repressor of p53.27,28 It is an E3 ligase
that promotes p53 ubiquitination and proteasomal degradation.
In addition, binding of Mdm2 to p53 can directly inhibit
the transcriptional activity of p53 through a number of
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mechanisms.29,30 Mdm2 is ubiquitinated and is degraded by the
proteasome.31 The proteasome consequently contributes to the
maintenance of the balance between levels of p53 and Mdm2.
This balance is critical for tumour suppression by p53 and has a
considerable impact on the magnitude of p53 activation in
response to cellular stresses.32–34 Inhibition of the proteasomal
degradation of p53 and enhanced degradation of Mdm2 are
involved in p53 activation in response to stress signals.35,36
Interventions that stabilize both p53 and Mdm2, including
inhibition of the proteolytic activity of the proteasome, can lead
to the accumulation of sufficient Mdm2 to repress the
transcriptional activity of p53.30,35,37
Despite the importance of the proteasome in the regulation of
p53, the pathways through which ubiquitinated p53 and Mdm2
are recruited to the proteasome have not been defined. There is
evidence that S5a influences p53 protein expression,38,39 but this
has not been investigated in detail. Consistent with a role in
recruitment of p53 to the proteasome, knockdown of the UBA/
UBL adaptor proteins hHR23A and hHR23B has been observed to
cause the accumulation of p53.40 However, in other studies, their
depletion resulted in a decrease in p53 levels.41–43 p53 and Mdm2
have been reported to bind to a number of proteasomal subunits
in a ubiquitin-independent manner.44–48 Mdm2 promotes
ubiquitination-independent association of p53 with the proteasome,
but an additional step requiring the ubiquitin ligase activity of Mdm2
is necessary for p53 degradation.46
Our investigation of the regulation of p53 by the deubiquitinat-
ing enzyme USP5 raised the possibility that there are differences
in proteasomal recognition of p53 and Mdm2.49 As a first step to
explore this, we have looked at the role of the proteasomal
ubiquitin receptor S5a. Targeting S5a inhibits p53 protein
degradation without affecting the stability of Mdm2. This results
in an increase in p53 expression and transcriptional activity. Our
data are consistent with a key role of S5a in the recognition of p53
by the proteasome. It is possible that degradation of Mdm2
normally proceeds through an S5a-independent mechanism, or an
alternative pathway of proteasomal recognition of Mdm2 may
compensate for loss of S5a.
RESULTS
S5a knockdown causes the accumulation of ubiquitinated p53
To investigate the pathway of proteasomal recognition of p53 and
Mdm2, the ubiquitin receptor S5a was knocked down using
synthetic siRNA. Blocking ubiquitin-dependent recognition of a
substrate by the proteasome should result in an increase in the
cellular level of the protein and in its ubiquitin-conjugated forms.
Consistent with this, depletion of S5a resulted in accumulation of
endogenous wild-type p53, and high-molecular weight p53
conjugates in A375 melanoma, MCF7 breast cancer and HCT116
colon cancer-derived cells (Figures 1a and b). S5a knockdown did
not decrease the protein levels of other intrinsic proteasomal
subunits (Supplementary Figure S1). In addition, as observed in
lower organisms,6,50–54 26S proteasomes can be assembled that
are depleted of S5a (Supplementary Figure S2). These data
indicate that the effects on p53 are a specific consequence of S5a
knockdown. Furthermore, activation of DNA damage pathways is
not responsible for the upregulation of p53 following knockdown
of S5a (Supplementary Figure S3).
S5a knockdown and bortezomib-mediated inhibition of the
proteolytic activity of the proteasome caused similar increases in
the level of p53 and high-molecular weight conjugates of p53
(Figure 1c). The effects of S5a depletion are thus consistent with
inhibition of the proteasomal degradation of p53. Bortezomib
caused greater accumulation of high-molecular weight ubiquitin
conjugates than S5a knockdown. This is in line with studies in
Saccharomyces cerevisiae which show that knockout of the yeast
homologue of S5a affects the degradation of only a subset of
ubiquitinated proteins targeted for proteasomal degradation.5,6
Inhibitors of the proteolytic activity of the proteasome can deplete
the pool of free ubiquitin.55–57 Indicative of a more limited effect
on protein degradation S5a knockdown did not reduce free
ubiquitin levels (Supplementary Figure S4).
Immunoprecipitation of p53 and western blotting with anti-
ubiquitin antibodies confirmed that the high-molecular weight
p53 conjugates accumulated after depletion of S5a contain
ubiquitin (Figure 1d). The pattern of conjugates detected by p53
and anti-ubiquitin antibodies differed to some extent. Higher-
molecular weight conjugates were more prominent in the
ubiquitin western blots of the immunoprecipitated p53. This is
likely to reflect the increasing ratio of ubiquitin to p53 epitopes in
the higher-molecular weight conjugates. There may also be
epitope masking of the ubiquitin molecules conjugated in the
closest proximity to p53.
Depletion of S5a selectively inhibits the degradation of p53
S5a knockdown inhibited p53 protein degradation while having no
effect on the rate of Mdm2 degradation in all three cell lines
examined (Figure 2a and Supplementary Figure S5). Mdm2 protein
expression was elevated by S5a knockdown (Figure 1). Mdm2 is a
p53 target gene and we show below that this increase in Mdm2
levels is due to transcriptional activation of p53. Combined S5a
knockdown and treatment with bortezomib also demonstrated
that Mdm2 continues to be degraded by the proteasome in cells
depleted of S5a (Supplementary Figure S6). This shows that Mdm2
is not degraded by a compensatory proteasome-independent
pathway. Mdm2 is a key regulator of p53 stability in the cell lines
used.58–60 Treatment of A375 cells with the specific Mdm2 inhibitor
nutlin-3 caused the accumulation of p53 (Supplementary Figures
S3 and S7a). In addition, double-knockdown experiments indicate
that p53 ubiquitination is Mdm2-dependent in cells depleted of
S5a (Supplementary Figure S7b).
To determine whether the differential effect on p53 and Mdm2
stability is simply a consequence of the degree of proteasome
impairment that is achieved by knockdown of intrinsic subunits of
the proteasome S9/PSMD11/Rpn6 and PSMB3/b3 were targeted.
The former protein is a subunit of the 19S RP that is required for RP
assembly.61 The latter protein is a component of the 20S core that is
required for core assembly.62 Knockdown of S9 or PSMB3 stabilized
both p53 and Mdm2 (Figure 2b). This shows that the differential
effect on degradation of p53 and Mdm2 is selective for knockdown
of S5a. It also confirms that the 19S RP and 20S core of the
proteasome are required for degradation of both p53 and Mdm2.
These data indicate that there is a differential requirement for
S5a in the proteasomal degradation of p53 and its E3 ligase
Mdm2. The degradation of p53 but not Mdm2 being highly
sensitive to depletion of S5a.
The ubiquitin-interacting motifs of S5a are required for
degradation of p53
S5a contains an N-terminal von Willebrand factor A domain that is
required for its association with the proteasome and two C-terminal
ubiquitin-interacting motifs (UIMs). Purified S5a associated in a UIM-
dependent manner with high-molecular weight conjugates of p53
(Figure 3). It was also observed that high-molecular weight
conjugates of Mdm2 can complex with S5a independently of
p53. This would appear to be at odds with the observation that
Mdm2 degradation is insensitive to S5a knockdown. However, it is
possible that there is loss of selectivity of S5a in vitro or that in vivo
there are S5a-independent preferential or compensatory pathways
for the proteasomal recruitment of Mdm2.
A C-terminal deletion of S5a lacking its UIM which can still be
incorporated into the proteasome has been used widely in lower
organisms to assess the contribution of the ubiquitin-binding
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activity of S5a homologues to protein degradation.5,6,16,17,63,64 A375
cells were infected with an adenovirus that produces an equivalent
deletion of human S5a (S5aDUIM) that lacks both UIMs. Co-
immunoprecipitation of multiple subunits of the 19S RP and the 20S
core with S5aDUIM shows that the S5a deletion is incorporated into
26S proteasomes (Figure 4a). Expression of S5aDUIM to a sufficient
level to prevent the association of endogenous S5a with the
proteasome would be predicted to act in a dominant-negative
manner and block S5a UIM-dependent protein degradation. Over-
expression of S5aDUIM in A375 cells caused the accumulation of
p53 and an increase in the level of high-molecular weight p53
conjugates (Figure 4b). Strikingly, overexpression of S5aDUIM
reduced the rate of p53 protein degradation without affecting the
stability of Mdm2 (Figure 4c). This suggests that the UIMs of S5a are
selectively required for the proteasomal degradation of p53. Ectopic
expression of S5aDUIM caused a dramatic decrease in the levels of
endogenous S5a (Figures 4b and c). Failure to properly incorporate
S5a into the 19S RP results in a decrease in S5a protein levels.62 It
may be the case that endogenous S5a that is displaced from the 19S
RP by S5aDUIM is more unstable than the 19S RP bound protein.
Figure 1. Depletion of S5a causes the accumulation of ubiquitinated p53. Cells were mock transfected ( ) or transfected with non-targeting
siRNA (control) or siRNA targeting S5a. siRNA S5a (A) and (B) are complementary to two different sequences in S5a. Unless otherwise indicated
in these and subsequent experiments cells were harvested for western blotting 48 h after transfection under denaturing conditions to prevent
protein deubiquitination. Where appropriate a short and an extended exposure of the western blot for p53 are presented in order to show
total p53 levels and high-molecular weight p53 conjugates. (a) In A375 cells knockdown of S5a caused the accumulation of p53 and p53
conjugates with kinetics that paralleled the decrease in S5a. (b) Depletion of S5a increased the level of p53 and p53 conjugates in A375, MCF7
and HCT116 cells. (c) A375 cells were transfected as shown and, where indicated, the proteasome inhibitor bortezomib (BZ; 50 nM) was added
7h before harvesting. These conditions are optimal for the effects of BZ on p53 levels and ubiquitination and on the general pattern of high-
molecular weight ubiquitin conjugates. BZ and knockdown of S5a cause a similar increase in p53 and p53 conjugates. (d) Lysates of A375 cells
were prepared under denaturing conditions to maintain protein ubiquitination and disrupt protein–protein interactions. Lysates were
incubated with pre-immune rabbit serum or anti-p53 antibody CM.1, and immunoprecipitates were analysed by western blotting for p53 (left
panel) or ubiquitin (right panel). High-molecular weight p53 conjugates detected after S5a knockdown contain ubiquitinated p53. A band
corresponding to antibody heavy chain that co-migrates with unmodified p53 is presented in the western blots.
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To further investigate the role of the UIMs of S5a in the
degradation of p53, the ability of ectopically expressed
wild-type S5a and S5a mutants to rescue the effect of
endogenous S5a knockdown was compared. A375 cells were
infected with doxycycline-inducible adenoviruses that encode
siRNA-resistant S5a constructs. The efficiency of infection was
verified by immunofluorescence (Supplementary Figure S8).
Partial restoration of wild-type S5a levels reduced p53 accumu-
lation (Figure 5). This indicates that increased p53 expression is
not due to an off-target effect of the S5a siRNA. In contrast,
ectopic expression of S5aDUIM to a comparable level did
not rescue the effect of S5a knockdown on p53 accumulation.
This confirms that the UIMs of S5a are required for the
degradation of p53.
A deletion of S5a (S5aUIM) lacking the N terminus, which
is required for incorporation into the proteasome17,39 but
retaining the UIMs, further increased p53 levels compared with
S5a knockdown. This mutant is able to associate with
high-molecular weight conjugates of p53 (Figure 3b). These
observations are consistent with further stabilization of p53
through sequestration away from the proteasome by S5aUIM. In
cell-free systems, S5a and S5aUIM can promote proteasomal
degradation by preventing the formation of non-degradable
forked ubiquitin chains.19 The inability of S5aUIM to rescue
indicates that accumulation of p53 following S5a knockdown is
not due to a role of the UIMs of S5a in preventing forked
ubiquitin chain formation.
Suppression of S5a activates p53
In A375 cells, knockdown of S5a results in the accumulation of
p53 in the nucleus (Figure 6a) and causes an increase in
Figure 2. Knockdown of S5a selectively inhibits the degradation of p53 without effects on the degradation of Mdm2. A375 cells were
transfected with non-targeting siRNA (control) or with siRNA targeting the indicated proteasomal subunits. Cells were treated with
cycloheximide (20 mg/ml) for the indicated time before harvesting. Independent duplicate 0min samples were analysed. The upper panels are
western blots (different exposures are shown so that protein levels in the absence of cycloheximide are matched). The lower panels show
quantification of the western blots. (a) S5a knockdown stabilizes p53 without affecting the stability of Mdm2. (b) Gross interference with the
function of the 19S RP by knockdown of S9 or the 20S core of the proteasome by depletion of PSMB3 caused the stabilization of both p53 and
Mdm2. The differential effect of S5a knockdown on the degradation of p53 and Mdm2 is selective in that it is not recapitulated by the
depletion of other proteasomal subunits.
S5a is required for the degradation of p53
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p53-responsive transcriptional reporter activity (Figure 6b). The
Mdm2 gene is a transcriptional target of p53. Consistent with
specific transcriptional activation of p53, knockdown of S5a
increased the level of the p53-responsive Mdm2 P2 mRNA but
had no affect on the level of p53-independent Mdm2 P1 mRNA
(Figure 5c). In addition, S5a depletion increased mRNA expression
of the p53 target genes p21 and Bax. HCT116 p53þ /þ and p53 /
cells were used to determine the p53 dependency of the effects of
S5a knockdown. S5a depletion resulted in a p53-dependent
increase in Mdm2 P2, p21 and Bax mRNA expression (Figure 7b).
Suppression of S5a increased Mdm2 protein levels in HCT116
p53þ /þ cells. However, little or no increase in Mdm2 protein
expression was observed in HCT116 p53 / cells following S5a
knockdown (Figure 7a). Similar results were observed in matched
Figure 3. S5a can associate with p53 and Mdm2 through its UIMs. Pulldown experiments were carried out using lysates of bortezomib-treated
cells as a source of correctly modified/ubiquitinated p53 and Mdm2. The inputs (10% of the lysate used per pulldown) and eluted material
were analysed by western blotting using anti-Mdm2 antibody 4B2 and anti-p53 antibody DO.1. Recombinant proteins used in the pulldown
experiments were analysed by SDS–polyacrylamide gel electrophoresis and Coomassie staining. (a) A375 lysates were incubated with 0.1, 0.3,
1, 3 and 10 mM GST-S5a or an equal amount of GST. High-molecular weight conjugates of p53 and Mdm2 were specifically pulled down by full-
length S5a. (b–d) Lysates were incubated with 3 mM GST-S5a or an equal amount of the indicated GST-fusion. (b) GST-S5a and an N-terminal
deletion (GST-S5aUIM), which retains both UIMs, associated with high-molecular weight conjugates of p53 and Mdm2. In contrast, a
C-terminal deletion (GST-S5aDUIM) that lacks both UIMs did not pulldown high-molecular weight conjugates of p53 or Mdm2. The association
of S5a with conjugates of p53 and Mdm2 requires its UIMs. (c) Extracts were incubated with nutlin-3 (10 mM) for 1 h before GST-pulldown to
interfere with the interaction between p53 and Mdm2. Nutlin-3 did not prevent the association of S5a with high-molecular weight conjugates
of p53 or Mdm2. (d) GST-S5a associates with Mdm2 in HCT116 p53 / cells. The interaction between Mdm2 high-molecular weight
conjugates and S5a does not require bridging by p53.
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control MCF7 cells, and MCF7 cells stably transfected with
dominant-negative truncated p53 (DD-p53) that attenuates the
activity of endogenous p53 (Supplementary Figure S9). The p53
target gene mRNA induction following S5a knockdown is similar to
that observed with p53-activating agents such as doxorubicin and
5-fluorouracil.37,65 These data show that S5a knockdown increases
Figure 4. Overexpression of a mutant S5a lacking UIMs stabilizes p53 but not Mdm2. A375 cells were infected with an adenovirus expressing
hrGFP alone (control) or a bicistronic adenovirus expressing hrGFP along with an HA-tagged deletion of S5a missing the UIMs (S5aDUIM) or
HA-tagged full-length S5a. (a) Cells were lysed under native conditions that maintain the integrity of the 26S proteasome. Lysates were
immunoprecipitated with an irrelevant control immunoglobulin G or an anti-HA antibody. The immunoprecipitates were analysed by western
blotting. The proteasomal subunits PSMA2/a2 and PSMB5/b5 (20S core), ADRM1/Rpn13, S2/PSMD2/Rpn1, S4/PSMC1/Rpt2 (19S base) and S9/
PSMD11/Rpn6 and S13/PSMD14/Rpn11 (19S lid) were specifically co-immunoprecipitated with HA-tagged S5aDUIM and S5a. This
demonstrates that HA full-length S5a and S5aDUIM are incorporated into the 26S proteasome. (b) A375 cell were infected with the indicated
adenoviruses at MOI of 150, 500 and 1500. Fourty-eight hours after infection, protein expression was analysed by western blotting. An anti-HA
antibody was use to detected S5aDUIM as it does not contain the epitope recognized by the S5a antibody used. Expression of S5aDUIM
caused a decrease in the level of endogenous S5a. This could be due to a reduction in protein stability when endogenous S5a is prevented
from associating with the proteasome. S5aDUIM increased the level of p53 and p53 conjugates. (c) Adenovirus-mediated ectopic expression
of S5aDUIM interfered with the degradation of p53 but had no affect on the degradation of Mdm2.
S5a is required for the degradation of p53
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p53 transcriptional activity, and that the increase in Mdm2 protein
expression following the suppression of S5a is due to the
transcriptional activation of p53.
Bortezomib treatment caused p53 accumulation (Figure 1 and
Figure 7a) but a relatively small increase in p53-responsive
transcriptional reporter activity, (Figure 6b) and it did not result
in a p53-dependent increase in p21 or Bax mRNA levels
(Figure 7b). This confirms that inhibition of the proteolytic activity
of the proteasome does not efficiently increase the transcriptional
activity of p53. However, bortezomib did cause a p53-dependent
increase in Mdm2 P2 mRNA, indicating, as observed previously,66
that proteasome inhibition can have p53 target gene-selective
effects. The use of a combination of bortezomib and nutlin-3
indicates that the transcriptional activity of p53 can be suppressed
by Mdm2 in cells in which the proteolytic activity of the
proteasome is inhibited (Supplementary Figure S10).
The effect of S5a knockdown on the cell cycle was investigated
in HCT116 cells. S5a knockdown caused a p53-dependent
decrease in the proportion of cells in S phase (Figures 7c and
7d). This demonstrates that p53 can have an important role in
reducing cell proliferation following the depletion of S5a.
DISCUSSION
Our study shows that the ubiquitin receptor S5a participates in the
recognition of ubiquitinated p53 by the proteasome. Suppression
of S5a increases p53 protein stability and causes the accumulation
of ubiquitinated p53. Furthermore, the UIMs of S5a are required
for p53 degradation. In contrast, degradation of Mdm2 by the
proteasome is unaffected by interfering with S5a. This demon-
strates that there is a difference in the pathways of proteasomal
recognition of p53 and its major E3 ligase Mdm2. Through
selective effects on the stability of p53 and Mdm2, targeting S5a
can result in more efficient transcriptional activation of p53 than
general proteasome inhibition.
Intrinsic proteasomal S5a may have the major role in p53
recognition. However, a significant proportion of S5a exists free of
the proteasome.16–19 It is thus possible that extraproteasomal S5a
participates in bringing ubiquitinated p53 to the proteasome.
Targeting of p53 to S5a could involve the interaction of
ubiquitinated p53 with a shuttle receptor. S5a binds directly to
polyubiquitin but can also bind to the UBL domain of UBA/UBL
adaptor proteins through the same UIMs. There is evidence both
for and against a role of the UBA/UBL adaptor proteins hHR23A
and hHR23B in the degradation of p53.40–43 Mdm2 can promote
the ubiquitin-independent association of p53 with the
proteasome.46 There may be handover of ubiquitinated p53
from Mdm2 to S5a. Intriguingly, ubiquitination of p53 causes a
decrease in the affinity of the interaction between p53 and
Mdm2.67 This could mediate the release of p53 from Mdm2 in
order to transfer it to S5a.
S5a is not essential for Mdm2 degradation by the proteasome.
Mdm2 maintains low levels of p53 in all the cell lines used,58–60
and we observed that it is required for the accumulation of
ubiquitinated p53 when S5a is knocked down. This shows for the
first time that S5a can be selectively involved in the recognition of
an E3 ligase and its substrate by the proteasome. S5a depletion
had a smaller effect on the general pattern of high-molecular
weight ubiquitin conjugates than inhibition of the proteolytic
activity of the proteasome, further indicating that targeting S5a in
human cells has selective effects on protein degradation by the
proteasome. These observations are consistent with the finding
that in S. cerevisiae, Rpn10, the yeast homologue of S5a, is required
for the proteasomal degradation of only a subset of ubiquitinated
proteins.5 In pulldown experiments, high-molecular weight
conjugates of Mdm2 associate with S5a. This may be due to loss
of specificity in vitro. However, it is possible that recruitment
pathway selectivity is determined upstream of S5a at the level of
ubiquitin-binding shuttle proteins. The selective interaction of
Mdm2 with a shuttle protein may result in its targeting to the
proteasome by an S5a-independent mechanism. Alternatively,
there may be redundancy in the pathways of proteasomal
recognition of Mdm2, and an additional receptor could
compensate for the loss of S5a.
Variations in the nature of the ubiquitin tag including the
degree of polyubiquitination and the type of inter-ubiquitin
crosslinks could provide the biochemical basis for differences in
the pathways of recruitment of p53 and Mdm2. A contributory
factor to differences in the ubiquitin tag could be that under at
Figure 5. Wild-type S5a rescues the effect of S5a knockdown on p53
levels. A375 cells were mock infected ( ) or infected with the
indicated Tet-On adenovirus expressing siRNA-resistant, HA-tagged
wild-type or mutant S5a. Where shown endogenous S5a was
knocked down using siRNA S5a(A). Doxycycline (DC) was then
added to the indicated concentrations to induce expression of the
S5a constructs. Equivalent exposures of western blots are shown.
The epitope recognized by the S5a antibody is deleted in S5aDUIM.
Consequently, an anti-HA antibody was use to compare the
expression of the different S5a constructs. In mock-infected cells,
DC had no effect on p53 or S5a protein levels. Despite being
expressed to similar levels, wild-type S5a but not a mutant, where
the UIMs of S5a are deleted (S5aDUIM), partially rescued the
increase in p53 expression resulting from knockdown of endogen-
ous S5a. The UIMs of S5a are required for p53 degradation. The
expression of S5a and (S5aDUIM) caused a decrease in the
remaining endogenous S5a. This indicates that a high proportion
of the cells were infected with each adenovirus, and that
endogenous S5a was displaced from the proteasome. A deletion
of S5a lacking the proteasome-binding regions but containing the
UIMs (S5aUIM) also failed to rescue p53 accumulation following
endogenous S5a knockdown. The position of migration of S5aUIM is
indicated by ‘*’. Instead, S5aUIM further increased p53 protein
expression, presumably through sequestration of p53 away from the
proteasome. Accumulation of p53 following S5a knockdown is not
due to the ability of the UIMs of S5a to prevent forked chain
ubiquitin formation. Expression of S5aUIM was lower than that for
the other S5a constructs. This is consistent with destabilization due
to exclusion from the proteasome.
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least some circumstances, endogenous Mdm2 ubiquitination is
not mediated by autoubiquitination but rather by other E3
ligases.68–70 Multiple types of ubiquitin modification can target
proteins for degradation by the proteasome.1 Ubiquitin-binding
proteins can display selectivity for ubiquitin chains of different
lengths and for ubiquitin chains generated through the linking of
different lysine residues.21,71,72 There may also be a direct
interaction between the substrates and the receptor or another
appropriately positioned subunit associated with the proteasome
that favours binding to a particular ubiquitin receptor. The
conjugation of other UBL modifiers to p53 or Mdm2 could also
influence the pathway of recognition.73 Several deubiquitinating
enzymes associate with the proteasome74 and could have
selective effects on substrate recognition.
Targeting S5a resulted in the transcriptional activation of p53
and can cause a p53-dependent decrease in cell proliferation.
Stabilization of p53 without effects on the stability of Mdm2
provides a mechanism for this increase in the activity of p53. This
alters the set point of the p53:Mdm2 feedback loop. The balance
between levels of p53 and Mdm2 has an important influence on
tumour suppression and the response of p53 to stress. By
providing a means to alter the relative stability of p53 and
Mdm2, differences in recognition of p53 and Mdm2 by the
proteasome could be important in p53 regulation. Modulation of
S5a or additional ubiquitin receptors selectively involved in the
recognition of p53, and Mdm2 could participate in the control of
p53 during tumour development and by cellular signals. S5a levels
are increased in cancer.75–77 The expression and splicing of S5a is
Figure 6. Knockdown of S5a causes the accumulation of p53 in the nucleus and increases p53-responsive transcript expression. A375 cells
were mock transfected ( ) or transfected with the indicated siRNA. (a) Cells were analysed by immunofluorescence using CM.1 to detect
endogenous p53 (shown in green) and DNA was stained with DAPI (shown in red). Depletion of S5a caused an increase in the level of nuclear
p53. (b) S5a knockdown increased the activity of a p53-responsive reporter driving the expression of bgalactosidase to a greater extent
than proteasome inhibition by 100 nM bortezomib (BZ). b-galactosidase activity was normalized to total protein levels and expressed as a
percentage of control (non-targeting siRNA). The values are mean±s.d. of three determinations. (c) siRNA-mediated suppression of S5a
caused an increase in the expression of p53 target genes p21 and Bax, and in the p53-responsive Mdm2 P2 transcript. Levels of the
p53-independent P1 Mdm2 transcript were unaffected. mRNA expression was quantified by real-time PCR. mRNA levels were normalized to
TATA box binding protein (TBP) and expressed as a percentage of control (non-targeting siRNA). The values are mean±s.d. of three
experiments.
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developmentally regulated.17,78 The ubiquitin/UBL-binding activity
of S5a homologues is controlled by stress-dependent mono-
ubiquitination in lower organisms.18,79 S5a is one of three 19S RP
subunits that are degraded in a caspase-dependent manner in
response to pro-apoptotic agents, possibly as part of a feed
forward pro-apoptotic response.80 Ubiquitin receptors are known
to be involved in DNA damage responses, members of the UBA/
UBL family are DNA damage inducible.81
Bortezomib, an inhibitor of the proteolytic activity of the
proteasome is used in the treatment of multiple myeloma and
mantle cell lymphoma. Work is underway to extend the use of
bortezomib to other cancers including solid tumours. There are
problems with de novo and acquired resistance, and also with
dose-limiting toxicities of bortezomib.82 Interfering with protein
degradation by targeting S5a may be of therapeutic benefit. In
some cell types, p53 can contribute to the anti-tumour activity of
bortezomib.83 However, inhibition of the proteolytic activity of the
proteasome can stabilize p53 without efficiently increasing its
transcriptional activity. A reason for this is the stabilization of
Mdm2 that causes the accumulation of sufficient Mdm2 to repress
p53 by direct binding.30,35,37 Owing to the selective stabilization of
p53 and not Mdm2 targeting S5a would have the advantage over
inhibitors of the proteolytic activity of the proteasome of more
robust transcriptional activation of p53. Interference with the
degradation of only a subset of proteasomal substrates may result
in a wider therapeutic window for targeting S5a. In addition,
targeting the proteasome in alternative ways, such as
antagonizing the ubiquitin/UBL-binding activity of S5a, could
overcome resistance to bortezomib. It would be of interest to
identify selective inhibitors of ubiquitin receptors. In support of
this possibility, there are significant variations in the amino-acid
residues in ubiquitin required for interacting with different
receptors.71,84,85 In addition, it may be possible to identify
antagonists that bind receptors at regions away from the direct
site of ubiquitin interaction.
This study shows that the ubiquitin receptor S5a can have a
selective role in the proteasomal degradation of ubiquitinated
proteins in human cells. S5a is required for the degradation of p53
Figure 7. p53 activation due to S5a knockdown can inhibit proliferation. HCT116 p53þ /þ and p53 / cells were transfected with siRNA or
incubated with 50 nM bortezomib (BZ) as shown. (a) Protein expression was analysed by western blotting. The extent of S5a knockdown was
similar in the two cell lines. Suppression of S5a caused an increase in p53 and Mdm2 protein levels in HCT116 p53þ /þ cells. The increase in
Mdm2 protein expression was p53-dependent. Proteasome inhibition by BZ caused a comparable increase in p53 protein levels. (b) Depletion
of S5a caused a p53-dependent increase in the mRNA expression of the p53 target genes Mdm2, p21 and Bax. BZ caused a p53-dependent
increase in Mdm2 P2 mRNA levels but not p21 or Bax. S5a knockdown is more efficient than proteasome inhibition at increasing the
transcriptional activity of p53 towards p21 and Bax. mRNA levels were quantified by real-time PCR. mRNA levels were normalized to TATA box
binding protein (TBP) and expressed as a percentage of control (non-targeting siRNA). The values are mean±s.d. of four experiments. (c, d)
Seventy-two hours after transfection with the indicated siRNA, HCT116 cells were pulse labelled with BrdU and analysed by flow cytometry.
Knockdown of S5a causes a p53-dependent decrease in the proportion of cells in S phase. (c) A representative experiment is shown. (d) The
proportion of cells in S phase was also expressed as a percentage of control (control siRNA transfection in the particular cell line). The values
are mean±s.d. of four experiments.
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but not its E3 ligase Mdm2. Additional work is required to
completely define the pathways of proteasomal recognition of
p53 and Mdm2, and to determine the contribution of ubiquitin
receptor regulation to the control of p53. It would also be of
interest to further investigate the therapeutic potential of
targeting S5a and any additional ubiquitin receptors that
co-operate with S5a in the recognition of p53 by the proteasome.
MATERIALS AND METHODS
Cell culture
A375, MCF7 and HCT116 cells were cultured as described previously.37,49
Cells were seeded onto six-well plates: A375 (6 104 cells/well), MCF7
(2 105 cells/well) and HCT116 (0.5–1 105 cells/well). Inhibitors:
bortezomib, (LC Laboratories, Woburn, MA, USA); nutlin-3, (Cayman
Chemicals, Ann Arbor, MI, USA).
Western blotting
Unless otherwise indicated, cell extracts were prepared by direct lysis into
SDS–urea electrophoresis sample buffer and western blotting was carried
out as described previously.49 Peroxidase-conjugated secondary antibodies
were supplied by Jackson ImmunoResearch Laboratories (Suffolk, UK) and
used at a dilution of 1/10 000.
Antibodies: Mdm2 (4B2) and p53 (DO.1 and CM.1), Moravian-Biotech-
nology (Brno, Czech Republic); p53 (SAPU), Scottish Antibody Production
Unit (Carluke, Scotland); actin (Ab-1, JLA20) and ubiquitin (P4D1, 05-944),
Millipore (Watford, UK); S5a/PSMD4/Rpn10 (S5a-18, PW9250) and PSMB5/
b5 (PW8895), Enzo Life Sciences (Exeter, UK); S5a (14899-1-AP), ADRM1/
Rpn13 (11468-1-AP), S2/PSMD2/Rpn1 (14748-1-AP), S4/PSMC1/Rpt2
(11196-1-AP), S9/PSMD11/Rpn6 (14786-1-AP) and S13/PSMD14/Rpn11
(12059-1-AP), Proteintech Group (Manchester, UK); ADRM1/Rpn13
(ab56852), HA (HA.C5, ab18181) and H2AX (ab11175), Abcam (Cambridge,
UK); GFP (7.1 and 13.1, 11814460001), Roche (Burgess Hill, UK); PSMA2/a2
(H-120, sc-67339), Santa Cruz (Heidelberg, Germany); phospho Ser-15 p53
(9284) and phospho Ser-139 histone H2AX (2577), Cell Signaling
Technology (Hitchin, UK).
Synthetic siRNA duplexes and transfections
ON-TARGETplus modified siRNA were purchased from Thermo Fisher
Scientific (Epsom, UK). S5a(A): 011365-05, S5a(B): 011365-07, S5a(C):
011365-06, S9: 011367-10, PSMB3: 017489-07, Mdm2(A): 003279-12 and
Mdm2(B): 003279-13. Transfection with synthetic siRNA duplexes (30 nM)
was carried out using Oligofectamine or Lipofectamine RNAiMAX (Life
Technologies, Paisley, UK) according to the manufacturer’s instructions.
Cells were harvested 48 h post transfection, unless otherwise indicated.
Pulldown experiments
Cells were treated with bortezomib (50 nM) for 6 h, washed twice in PBS
and lysed in buffer 1: 20mM HEPES (pH 7.5), 0.1% NP-40, 100mM NaCl,
5mM EDTA, 10mM NaF, 10mM Na-pyrophosphate, 10mM b-glyceropho-
sphate, complete protease inhibitor cocktail (Roche, Welwyn Garden City,
UK) containing 10mM NEM. This concentration of NEM was found to be the
minimum required to maintain p53 ubiquitination over the course of the
assay. Lysis was carried out on ice for 20min with occasional vortexing and
the lysates were centrifuged (14 000 g, 15min, 4 1C). The unreacted NEM in
the supernatants was neutralized by the addition of DTT to a final
concentration of 10mM. The supernatants (350 ml total volume) were
incubated for 2 h at 4 1C with the indicated concentration of bacterially
expressed GST or GST-fusion protein pre-bound to 20 ml of glutathione-
sepharose beads (GE Healthcare, Little Chalfont, UK). The beads were
washed three times in buffer 1 containing 1mM DTT and eluted in SDS–
urea sample buffer.
Adenovirus infection
Adenoviruses were generated expressing C-terminally HA-tagged: wild-
type S5a, S5aDUIM (residues 1 to 195 of S5a, which lacks both UIMs) and
S5aUIM (residues 196–377 of S5a that lacks the proteasome-binding region
but contains both UIMs). Adenoviruses were constructed using the AdEasy
system (Agilent Technologies, Stockport, UK) or Tet-On 3G Inducible
Adeno-X Adenoviral System 3 (Clontech, Saint-Germain-en-Laye, France).
Where necessary siRNA-resistant forms of S5a were generated by
introducing silent mutations at positions 8 (A to G) and 11 (G to C) of
the siRNA S5a(A) target sequence.
For overexpression experiments, the normal cell growth medium was
replaced with medium containing 2% foetal bovine serum, and cells were
infected with AdEasy viruses at a multiplicity of infection (MOI) of 1000
unless otherwise indicated. After 4 h, cells were washed twice in PBS and
returned to normal growth medium. Cells were harvested 40 h after
infection. For siRNA rescue, experiments cells were infected with
adenoviruses at a MOI of 2000, 6–8 h after plating. After 16 h, siRNA
transfection was carried out using Lipofectamine RNAiMAX. Four hours
later, doxycycline was added to the indicated concentrations. Cells were
harvested 40 h after doxycycline addition.
Immunoprecipitation
For proteasome immunoprecipitation, cells were washed twice in PBS and
lysed in buffer 2: 20mM Tris (pH 7.5), 0.1% NP-40, 5mM MgCl2, 10mM NaF,
10mM Na-pyrophosphate, 10mM b-glycerophosphate, 20% glycerol, 2mM
ATP, 1mM DTT, complete protease inhibitor cocktail Roche. ATP and
glycerol contribute to maintaining the integrity of the 26S proteasome.
Lysis was carried out on ice for 15min with occasional vortexing. The
lysates were centrifuged (14 000 g, 15min, 4 1C). The pooled supernatants
from one six-well plate (total volume 350ml) were then incubated for 1 h at
4 1C with agarose beads covalently coupled to control immunoglobulin G,
anti- PSMA2 antibody (MCP21, PW8335, Enzo Life Sciences) or anti-HA
antibody (26181, Thermo Fisher Scientific). The beads were washed three
times with buffer 2 and eluted in SDS–urea sample buffer. To detect
ubiquitination of endogenous p53 cells were lysed under denaturing
conditions and immunoprecipitation of p53 carried out as described
previously.49
Immunofluorescence
To detect p53, cells were fixed with ice-cold methanol–acetone and
staining was carried out as described previously.37
Quantitative detection of b-galactosidase
The assay was performed as described previously49
RNA preparation and PCR
Total RNA was extracted using RNeasy columns (Qiagen, Crawley, UK),
reverse transcription was carried out using random primers and
quantitative PCR was performed as described previously.49,86,87
Flow cytometry
Flow cytometry analysis of cells was performed as described previously.88
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